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Background: A survival paradox between Stage IIB/C and Stage IIIA colon cancers exists. It is unclear how
adequate lymph nodes dissection (LN) and post-surgery chemotherapy contribute to the survival paradox.
We intended to assess the impact of these two factors on the survival paradox.
Results: We evaluated 34,999 patients diagnosed with stage IIIA or stage IIB/C colon cancer in 2003–2012
from the National Cancer Data Base. The 5-year overall survival (OS) was 73.5 % for stage IIIA and 51.1 %
for stage IIB/C (P < 0.0001). The 5-year OS was 84.1 % for stage IIIA with post-surgery chemotherapy, 70.8 %
for stage IIB/C with ≥ 12 LNs retrieved with chemotherapy, 53.9 % for stage IIB/C < 12 LNs with chemotherapy,
49.5 % for stage IIIA without chemotherapy, 43.7 % for stage IIB/C ≥ 12 LNs retrieved without chemotherapy,
to 27.7 % for stage IIB/C < 12 LNs without chemotherapy. Even among stage IIB/C who had optimal
treatment (≥12 LNs retrieved, received chemotherapy), OS remains lower than stage IIIA with chemotherapy.
After adjusting LN dissection and chemotherapy in addition to the adjustment of other clinical factors,
the survival paradox was reduced from HR = 1.76 (95 % CI: 1.68–1.85) to HR 1.51 (95 % CI: 1.44–1.59).
Conclusions: LN dissection and post-surgery chemotherapy partially explained the survival paradox. More
research is warranted to identify other factors that contribute to this paradox. Future iteration of TNM staging
system should take this into consideration.
Keywords: Colon cancer, Stage IIB/C colon cancer, Stage IIIA colon cancerBackground
For most solid cancers, the 7th edition of the Ameri-
can Joint Committee on Cancer (AJCC) TNM staging
system accurately prognosticates outcome with lower
stage cancers having better prognosis than higher
stage cancers [1]. However, colon cancer is one of the
few exceptions. For stage IIB/C and stage IIIA, there* Correspondence: ppeddi@lsuhsc.edu
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vival for patients with stage IIIA is approximately
70 % versus 46–61 % for stage IIB/C [1]. Such a
paradox is attributed to several factors according to
previous studies, such as stage migration due to inad-
equate nodal sampling or lack of systemic therapy for
stage IIB/C [2, 6]. We hypothesize that stage IIB/C is
inherently more aggressive than stage IIIA, even after
adjusting for receipt of chemotherapy and adequate
nodal sampling. We propose to assess the simultan-
eous contribution of lymph node dissection andle is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Overall Survival for Stage IIB/C and Stage IIIA: Note that there
is a statistically significant survival difference between stage IIIA and
stage IIB/C (P < 0.0001). However, there is no significant difference
between stage IIB and stage IIC (P = 0.46)




The nationally recognized National Cancer Data Base
(NCDB) is a joint project of the Commission of Cancer
(CoC) of the American College of Surgeons and the
American Cancer Society. More than 1500 CoC-
accredited facilities in the U.S. contribute clinical informa-
tion to the database. Approximately 70 % of newly
diagnosed cancer cases in the U.S and 30 million
historical records are captured in the database
(https://www.facs.org/quality-programs/cancer/ncdb/puf).
The data in the Participant User File (PUF) were
de-identified and in compliance with the privacy require-
ments of the Health Insurance Portability and Account-
ability Act (HIPAA). The study was exempted from
Institutional Review Board (IRB) approval by the Louisi-
ana State University Health Sciences Center-Shreveport.
Study population
A cohort of 34,999 cases of stage IIIA or stage IIB/C
colon cancer cases (ICD-0-3; C18.0, C18.2 to C.18.9)
diagnosed in 2003–2012 in the NCDB were analyzed
to determine significant factors associated with 5-year
overall survival (OS). Patients were staged based on
the 6th and 7th edition of the AJCC/TNM staging
system [1]. Patients were further divided into six
subgroups based on number of lymph nodes (LNs)
dissected and status of chemotherapy use: (1) Stage IIIA +
chemotherapy, (2) Stage IIB/C, ≥ 12 LNs + chemotherapy,
(3) Stage IIB/C, < 12 LNs + chemotherapy, (4) Stage
IIIA, no chemotherapy, (5) Stage IIB/C, ≥ 12 LNs, no
chemotherapy, and (6) Stage IIB/C, < 12 LNs, no
chemotherapy.
According to the NCDB’s PUF dictionary [7], comor-
bidity was reported as Charlson/Deyo score: 0, 1 or 2 [8,
9]. Age at diagnosis, race, facility type, facility location,
urban/rural, insurance status, income and education
levels for each patient’s area of residence, comorbid
conditions, anatomic site, tumor grade, surgical margin
status, chemotherapy, and number of lymph nodes
retrieved were variables selected for evaluation. NCDB
does not have information on cause-specific survival and
therefore, overall survival was calculated based on death
from all causes.
Statistical Analysis
We calculated the propensity scores by stage IIB/C and
stage IIIA using a multivariable logistic regression model.
Only cases with matched scores based on potential
confounders (i.e., age, race, distance from cancer reporting
facility, facility type, facility location, rural/urban,insurance, income, education, comorbidity, primary site,
grade, and surgical margins) were included in the multi-
variable analysis. The purpose of this approach was to
ensure that stage IIB/C and stage IIIA cases were compar-
able to reduce potential confounder effect. Descriptive
statistics for the different variable were presented. Univari-
able analysis of each variable was performed using chi-
square test for categorical data and ANOVA for numerical
data. The Kaplan-Meier method was used for survival
analysis. Univariable Cox proportional hazard regression
was used to identify factors significantly associated with
the risk of death for all causes. Multivariable Cox propor-
tional hazards regression analysis was used to determine
independent significant factors associated with the risk of
death for all causes, and hazard ratios (HR) and confi-
dence intervals (CI) were calculated. Insurance status,
income and education levels for each patient’s area of
residence were also adjusted in the multivariable analysis.
Results are based on adjusted variables. A p-value ≤ 0.05
was considered statistically significant. All statistical ana-
lyses were performed using SAS Version 9.4 statistical
software, (SAS Institute Inc., Cary, NC, U.S.A., 2013).
Results
The median follow-up was 39 months. Figure 1 demon-
strates the Kaplan-Meier OS curve for stage IIB, stage IIC,
and stage IIIA. Note that there is a significant survival dif-
ference between stage IIB/C and stage IIIA (P < 0.0001),
although there was no significant survival difference
between stage IIB and stage IIC (P = 0.46). Figure 2
demonstrates the Kaplan-Meier OS curve for the 6
subgroups which were defined by the number lymph
nodes retrieved (<12 LNs vs ≥12 LNs) and whether or not
systemic chemotherapy was given. For the entire cohort,
the 5-year OS rate was 73.5 % for stage IIIA and 51.1 %
for stage IIB/C. For the subgroups, the 5-year OS are
84.1 % for stage IIIA plus chemotherapy, 70.8 % for stage
Fig. 2 Overall Survival for the Six Subgroups of Patients with Stage
IIB/C and Stage IIIA Colon Cancer. The 5-year OS are 84.1 % for stage
IIIA plus chemotherapy, 70.8 % for stage IIB/C with ≥ 12 LNs plus
chemotherapy, 53.9 % for stage IIB/C < 12 LNs plus chemotherapy,
49.5 % for stage IIIA without chemotherapy, 43.7 % for stage IIB/C≥
12 LNs without chemotherapy, and 27.7 % for stage IIB/C < 12 LNs
without chemotherapy (P< 0.0001). The median survival has not been
reached by the end of follow up (132 months) for stage IIIA with
chemotherapy, 122.6 months for stage IIB/C, ≥ 12 LNs with
chemotherapy, 72.5 months for stage IIB/C, < 12 LNs with chemotherapy,
58.9 months for stage IIIA without chemotherapy, 46.5 months for stage
IIB/C, ≥ 12 LNs without chemotherapy, and 23.0 months for stage
IIB/C, < 12 LNs without chemotherapy
Chu et al. BMC Cancer  (2016) 16:460 Page 3 of 9IIB/C with ≥ 12 LNs plus chemotherapy, 53.9 % for stage
IIB/C < 12 LNs plus chemotherapy, 49.5 % for stage IIIA
without chemotherapy, 43.7 % for stage IIB/C ≥ 12 LNs
without chemotherapy, and 27.7 % for stage IIB/C < 12
LNs without chemotherapy (P < 0.0001). The median
survival has not been reached by the end of follow up
(132 months) for stage IIIA with chemotherapy; it was
122.6 months for stage IIB/C, ≥ 12 LNs with chemotherapy,
72.5 months for stage IIB/C, < 12 LNs with chemotherapy,
58.9 months for stage IIIA without chemotherapy,
46.5 months for stage IIB/C, ≥ 12 LNs without chemother-
apy, and 23.0 months for stage IIB/C, < 12 LNs without
chemotherapy.
The poorest survival subgroup was stage IIB/C with < 12
LNs retrieved and without receipt of adjuvant chemother-
apy. Note that even when patients with stage IIB/C
received optimal treatment (≥12 LNs retrieved and receipt
of chemotherapy), their OS remains significantly lower
than those with stage IIIA who had chemotherapy (Fig. 2).
Table 1 compares the demographic and therapeutic
characteristics of stage IIB/C and stage III A before and
after matching. Note that the two groups were fairly
balanced after matching. Table 2 is a univariable analysis
of factors associated with survival and Table 3 is the
multivariable analysis based on the adjusted matchedanalysis. Note that stage IIB/C is an independent
predictor of worse outcome compared to stage IIIA.
T-stage and N-stage were not included because they
were co-linear with stage of disease. Other independent
factors associated with high hazard ratio include less
than 12 lymph nodes retrieved, lack of receipt of chemo-
therapy, and positive margins. Before including LN
dissection and chemotherapy in the multivariable model,
the HR of stage IIB/C versus stage IIIA was 1.76 (95 %
CI: 1.68–1.85). After adjusting for LN dissection and
chemotherapy in addition to the adjustment of clinical
variables included in Table 3, the HR was reduced to
1.51 (95 % CI: 1.44–1.59). Additional adjustment of
demographic variables in Table 3 did not change the HR
much (HR = 1.52; 95 % CI: 1.44–1.60).
Discussion
Accurate cancer staging at the time of diagnosis assists
clinicians to predict survival, impart prognostic informa-
tion, and select the most effective treatments [10]. The
last three decades, the American Joint Committee on
Cancer (AJCC) has undergone multiple iterations. AJCC
5th edition cancer staging system had only four categor-
ies for colon cancer, based on tumor-node-metastasis
(TNM) classification (Stages I, II, III, IV) [11]. In 2002,
AJCC 6th edition subdivided stage II into IIA (T3N0)
and IIB (T4N0) [12], but in 2000, the colorectal working
group subdivided T4 into T4a (tumor penetrates the
surface of the visceral peritoneum) and T4b (tumor
directly invades or is histologically adherent to other
organs or structures) [13] based on data that found that
peritoneal involvement had an adverse outcome [14].
The latest AJCC 7th edition published in 2010 further
refined colorectal cancer staging by dividing N1 into
N1a (metastasis in 1 node) and N1b (metastasis in 2–3
nodes), and N2 into N2a (metastasis in 4–6 nodes) and
N2b (metastasis in ≥ 7 nodes). Consequently, stage II
becomes IIA (T3N0), IIB (T4aN0), or IIC (T4bN0) and
stage III becomes IIIA (T1-2 N1, T1N2a), IIIB (T3-4 N1,
T2-3N2a, T1-2N2b), and IIIC (T4aN2a, T3-T4aN2b,
T4bN1-2) [1].
Even with the latest iteration of AJCC, the OS for
stage IIB/C remains lower than those with stage IIIA;
the OS for stage IIB was 60.6 % versus 45.7 % for stage
IIC and 67.2 to 73.7 % for stage IIIA [1]. Several groups
attributed the survival paradox to either stage migration
or lack of receipt of systemic therapy [2–6]. The implica-
tion is that if those with stage IIB/C received adequate
lymph node dissection and adjuvant chemotherapy, their
survival would have been better than those with stage III
disease. No studies have demonstrated whether such is
the case. Because the assumption has not been chal-
lenged, there is little impetus to revise the TNM staging
system to account for the survival paradox. However,
Table 1 Comparison of demographic and therapeutic characteristics of stage IIB/C and stage IIIA
Before matching After matching
Variable Stage IIB/C Stage IIIA P Stage IIB/C Stage IIIA P
No. of patients (%) 18,609 (53.2) 16,390 (46.8) 11,409 (50.0) 11,409 (50.0)
Age <.0001 0.94
18–49 1,678 (9.0) 1424 (8.7) 935 (8.2) 920 (8.1)
50–64 4,628 (24.9) 5284 (32.2) 2,979 (26.1) 3,016 (26.4)
65–74 4,368 (23.5) 4419 (27.0) 2,957 (25.9) 2,956 (25.9)
75 and more 7,935 (42.6) 5263 (32.1) 4,538 (39.8) 4,517 (39.6)
Distance from cancer reporting facility 0.06 0.58
<50 miles 16,909 (92.9) 15,015 (93.4) 10,630 (93.2) 10,651 (93.4)
≥50 miles 1,303 (7.2) 1,066 (6.6) 779 (6.8) 758 (6.6)
Race/Ethnicity <.0001 0.93
White 15,964 (86.5) 13,450 (82.8) 9,785 (85.8) 9,770 (85.6)
Black 1,965 (10.6) 2,197 (13.5) 1,283 (11.3) 1,308 (11.5)
American Indian, Aleutian, or Eskimo 53 (0.3) 36 (0.2) 27 (0.2) 31 (0.3)
Asian or Pacific Islander 390 (2.1) 456 (2.8) 261 (2.3) 251 (2.2)
Other 89 (0.5) 100 (0.6) 53 (0.5) 49 (0.4)
Facility Type 0.02 0.90
Community cancer program 2,715 (14.6) 2,239 (13.7) 1,565 (13.7) 1,588 (13.9)
Comprehensive community cancer center 11,044 (59.4) 9,700 (59.2) 6,815 (59.7) 6,804 (59.6)
Academic research program 4,825 (25.9) 4,432 (27.0) 3,029 (26.6) 3,017 (26.4)
Other specified types of cancer program 25 (0.1) 19 (0.1)
Facility Location <.0001 0.99
New England 1,335 (7.2) 886 (5.4) 678 (5.9) 692 (6.1)
Mid Atlantic 2,971 (16.0) 2,402 (14.7) 1,814 (15.9) 1,809 (15.9)
South Atlantic 3,835 (20.6) 3,715 (22.7) 2,352 (20.6) 2,391 (21.0)
East North Central 3,580 (19.2) 3,127 (19.1) 2,174 (19.1) 2,201 (19.3)
East South Central 1,162 (6.2) 1,186 (7.2) 788 (6.9) 786 (6.9)
West North Central 1,555 (8.4) 1,333 (8.1) 1,035 (9.1) 1,002 (8.8)
West South Central 1,487 (8.0) 1,391 (8.5) 942 (8.3) 938 (8.2)
Mountain 779 (4.2) 678 (4.1) 440 (3.9) 438 (3.8)
Pacific 1,905 (10.2) 1,672 (10.2) 1,186 (10.4) 1,152 (10.1)
Urban/Rural Location 0.05 0.96
Metro ≥1 million 9,488 (53.0) 8,380 (53.1) 6,039 (52.9) 6,028 (52.8)
Metro 250 k to 1 million 3,863 (21.6) 3,556 (22.5) 2,539 (22.3) 2,554 (22.4)
Urban <250 k 1,766 (9.9) 1,516 (9.6) 1,104 (9.7) 1,112 (9.8)
Urban≥ 20 k adjacent metro 731 (4.1) 657 (4.2) 460 (4.0) 476 (4.2)
Urban≥ 20 k not adjacent metro 262 (1.5) 221 (1.4) 182 (1.6) 175 (1.5)
Urban <20 k adjacent metro 957 (5.4) 751 (4.8) 577 (5.1) 572 (5.0)
Urban <20 k not adjacent metro 454 (2.5) 387 (2.5) 286 (2.5) 258 (2.3)
Rural <2500 adjacent metro 164 (0.9) 169 (1.1) 108 (1.0) 109 (1.0)
Rural <2500 not adjacent metro 212 (1.2) 154 (1.0) 114 (1.0) 125 (1.1)
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Table 1 Comparison of demographic and therapeutic characteristics of stage IIB/C and stage IIIA (Continued)
Comorbidities <.0001 0.61
0 12,872 (69.2) 11,665 (71.2) 7,905 (69.3) 7,962 (69.8)
1 4,185 (22.5) 3,537 (21.6) 2,576 (22.6) 2,513 (22.0)
2 1,552 (8.3) 1,188 (7.3) 928 (8.1) 934 (8.2)
Primary Site <.0001 0.99
Cecum 4,917 (26.4) 3,941 (24.1) 3,077 (27.0) 3,077 (27.0)
Ascending Colon 2,876 (15.5) 3,140 (19.2) 1,969 (17.3) 1,992 (17.5)
Hepatic Flexure 748 (4.0) 608 (3.7) 473 (4.2) 461 (4.0)
Transverse Colon 2,061 (11.1) 1,154 (7.0) 1,031 (9.0) 991 (8.7)
Splenic Flexure 786 (4.2) 366 (2.2) 312 (2.7) 327 (2.9)
Descending Colon 1,161 (6.2) 960 (5.9) 705 (6.2) 706 (6.2)
Sigmoid Colon 5,324 (28.6) 5,756 (35.1) 3,524 (30.9) 3,535 (31.0)
Overlapping Lesions 369 (2.0) 140 (0.9) 120 (1.1) 121 (1.1)
Not Otherwise Specified 367 (2.0) 325 (2.0) 198 (1.7) 199 (1.7)
Grade <.0001 0.87
Well differentiated 1,506 (8.4) 1,779 (11.4) 1,087 (9.5) 1,084 (9.5)
Moderately differentiated 11,868 (66.0) 11,226 (71.9) 8,007 (70.2) 8,049 (70.6)
Poorly differentiated 4,004 (22.3) 2,381 (15.3) 2,084 (18.3) 2,059 (18.1)
Undifferentiated, anaplastic 611 (3.4) 230 (1.5) 231 (2.0) 217 (1.9)
Surgical Margins <.0001 0.87
No residual tumor 14992 (82.6) 16,012 (98.8) 11,243 (98.6) 11,246 (98.6)
With Residual tumor 3156 (17.4) 190 (1.2) 166 (1.5) 163 (1.4)
Regional Lymph Nodes Examined <.0001 <.0001
0–11 4,399 (23.8) 4,867 (29.9) 2,422 (21.3) 3,298 (29.0)
12–90 14,101 (76.2) 11,434 (70.1) 8,944 (78.7) 8,078 (71.0)
Chemotherapy <.0001 <.0001
None 10,423 (58.7) 4,807 (30.5) 6,362 (58.4) 3,659 (33.3)
Yes 7,335 (41.3) 10,975 (69.5) 4,525 (41.6) 7,327 (66.7)
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our cohorts based not only on receipt of chemotherapy,
but also on the number of lymph nodes retrieved. To our
knowledge, ours is the first and the largest dataset that
assesses how these two factors, when combined, contrib-
ute to the paradox. Surprisingly, we found that even when
adequate lymph nodes were retrieved and chemotherapy
was administered, the survival paradox persists. What this
suggests is that T4N0 lesions (i.e. stage IIB/C) may be
inherently more aggressive than stage IIIA, although
further research is necessary to delineate the root cause of
the poorer survival among them.
Positive margins portend a poor outcome [15].
Inadequate resection of locally advanced lesions (i.e. T4)
can lead to positive surgical margins, especially if an
en-bloc resection was not performed [16]. In our study,
positive margins impart a 56 % increased risk of death
compared to negative margins. What impact surgical
margins have on the paradox for optimally treatedpatients with stage IIB/C colon cancer will be the subject
of our next investigation.
The role of adjuvant chemotherapy for patients with
resected stage II colon cancer remains controversial.
The 5-year OS following definitive colectomy for stage II
colon cancer is in the range of 85-89 % [17]. Whether
adjuvant systemic therapy can further improve this rate
remains an area of intense investigation. Besides the
QUASAR (Quick and Simple and Reliable) trial [18],
which was a phase III trial that found OS benefit for
patients with Stage II colon cancer, multiple other ran-
domized trials as well as meta-analysis found no such
significant advantage with chemotherapy [17, 19–25].
Although the commonly cited QUASAR trial (Quick
and Simple and Reliable) showed an absolute improve-
ment of 3.6 % for stage II colon cancer that received
adjuvant therapy, the trial had several limitations [18].
Approximately 8.5 % of 3,239 patients who were thought
to have stage II colon cancer actually had stage I or III
Table 2 Univariable analysis of factors associated with overall survival
Before matching After matching
Variable HR 95 % CI P-value HR 95 % CI P-value
Stage
Stage IIB/C 2.15 (2.07, 2.24) <.0001 1.70 (1.62, 1.78) <.0001
Stage IIIA 1.00 – – 1.00 – –
Age
18–49 1.00 – – 1.00 – –
50–64 1.30 (1.17, 1.45) <.0001 1.41 (1.22, 1.63) <.0001
65–74 2.23 (2.02, 2.48) <.0001 2.48 (2.16, 2.86) <.0001
75 and more 4.86 (4.41, 5.37) <.0001 5.12 (4.47, 5.87) <.0001
Race/ Ethnicity
White 1.00 – – 1.00 – –
Black 0.96 (0.91, 1.02) 0.19 1.06 (0.98, 1.14) 0.14
American Indian, Aleutian, or Eskimo 0.90 (0.61, 1.33) 0.60 0.93 (0.58, 1.47) 0.75
Asian or Pacific Islander 0.55 (0.47, 0.64) <.0001 0.62 (0.50, 0.75) <.0001
Other 0.63 (0.46, 0.87) 0.005 0.64 (0.41, 0.99) 0.05
Facility Type
Community cancer program 1.39 (1.31, 1.48) <.0001 1.40 (1.30, 1.52) <.0001
Comprehensive community cancer center 1.21 (1.16, 1.26) <.0001 1.24 (1.17, 1.31) <.0001
Academic research program 1.00 – – 1.00 – –
Facility Location
New England 1.08 (0.99, 1.18) 0.10 0.94 (0.84, 1.06) 0.32
Mid Atlantic 1.07 (0.99, 1.16) 0.07 0.98 (0.89, 1.08) 0.68
South Atlantic 1.06 (0.99, 1.13) 0.12 1.00 (0.92, 1.09) 0.98
East North Central 1.10 (1.03, 1.18) 0.008 1.04 (0.95, 1.14) 0.39
East South Central 1.09 (0.998, 1.20) 0.05 1.08 (0.97, 1.21) 0.16
West North Central 1.10 (1.005, 1.19) 0.04 1.04 (0.94, 1.16) 0.43
West South Central 1.01 (0.92, 1.11) 0.80 0.99 (0.89, 1.11) 0.84
Mountain 0.93 (0.83, 1.04) 0.20 0.87 (0.75, 1.01) 0.06
Pacific 1.00 – – 1.00 – –
Urban/Rural Location
Metro ≥1 million 1.00 – – 1.00 – –
Metro 250 k to 1 million 1.07 (1.02, 1.12) 0.008 1.09 (1.03, 1.15) 0.004
Urban <250 k 1.07 (1.004, 1.14) 0.04 1.06 (0.98, 1.14) 0.17
Urban≥ 20 k adjacent metro 1.10 (1.002, 1.21) 0.046 1.10 (0.98, 1.24) 0.09
Urban≥ 20 k not adjacent metro 1.04 (0.89, 1.22) 0.65 1.05 (0.87, 1.26) 0.63
Urban <20 k adjacent metro 1.13 (1.04, 1.23) 0.006 1.06 (0.95, 1.18) 0.30
Urban <20 k not adjacent metro 1.23 (1.10, 1.38) 0.0005 1.32 (1.15, 1.52) 0.0001
Rural <2500 adjacent metro 1.02 (0.85, 1.24) 0.81 0.88 (0.68, 1.14) 0.33
Rural <2500 not adjacent metro 1.12 (0.94, 1.33) 0.21 1.06 (0.85, 1.32) 0.58
Comorbidities
0 1.00 – – 1.00 – –
1 1.46 (1.40, 1.53) <.0001 1.49 (1.42, 1.58) <.0001
2 2.29 (2.16, 2.42) <.0001 2.29 (2.13, 2.46) <.0001
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Table 2 Univariable analysis of factors associated with overall survival (Continued)
Primary Site
Cecum 1.00 – – 1.00 – –
Ascending Colon 0.96 (0.91, 1.02) 0.15 1.04 (0.97, 1.11) 0.30
Hepatic Flexure 0.97 (0.88, 1.07) 0.51 0.95 (0.84, 1.07) 0.39
Transverse Colon 1.07 (0.997, 1.14) 0.06 0.93 (0.85, 1.02) 0.11
Splenic Flexure 1.07 (0.96, 1.18) 0.23 0.90 (0.77, 1.04) 0.15
Descending Colon 0.85 (0.78, 0.93) 0.0003 0.85 (0.77, 0.95) 0.003
Sigmoid Colon 0.76 (0.72, 0.80) <.0001 0.82 (0.77, 0.87) <.0001
Overlapping Lesions 1.19 (1.03, 1.38) 0.02 0.80 (0.62, 1.03) 0.08
Not Otherwise Specified 1.14 (1.004, 1.29) 0.04 1.13 (0.95, 1.33) 0.17
Grade
Well differentiated 1.00 – – 1.00 – –
Moderately differentiated 1.09 (1.02, 1.16) 0.01 1.04 (0.96, 1.13) 0.37
Poorly differentiated 1.39 (1.29, 1.50) <.0001 1.11 (1.01, 1.22) 0.03
Undifferentiated, anaplastic 1.74 (1.53, 1.97) <.0001 1.23 (1.02, 1.48) 0.03
Surgical Margins
No residual tumor 1.00 – – 1.00 – –
With Residual tumor 1.91 (1.81, 2.02) <.0001 1.24 (1.03, 1.49) 0.02
Readmission within 30 days of Surgery
Not readmitted 1.00 – – 1.00 – –
Readmitted 1.15 (1.08, 1.22) <.0001 1.13 (1.05, 1.22) 0.002
Regional Lymph Nodes Examined
0–11 1.34 (1.29, 1.39) <.0001 1.29 (1.23, 1.35) <.0001
12–90 1.00 – – 1.00 – –
Chemotherapy
Yes 1.00 – – 1.00 – –
No 3.55 (3.41, 3.70) <.0001 3.49 (3.32, 3.67) <.0001
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patients received radiation therapy) [18]. To our know-
ledge, our analysis is the first to demonstrate a survival
advantage of using adjuvant chemotherapy for stage II
disease, but only for those with stage IIB/C colon cancer
since we have 138,572 stage IIA patients in NCDB. Our
data lend support to the American Society of Clinical
Oncology’s recommendation of postoperative chemother-
apy for patients with T4 tumors [26]. Of interest is that
even when optimal treatment was rendered to those with
stage IIB/C disease, their OS remains significantly lower
than those with stage IIIA who had chemotherapy. Other
factors that contribute to the survival paradox will need to
be further investigated. Given our provocative data, we
believe that randomized control studies are needed to
determine whether there is a survival advantage of using
adjuvant chemotherapy for stage II colon cancer.
One of the limitations of our study is the lack of
recurrence data since this is not recorded in the NCDB.
Additionally, we do not have specific causes of deathand therefore it is plausible that deaths may not be
related to cancer. We also do not have data on other
factors such as microsatellite instability (MSI), preopera-
tive CEA level, whether or not patients presented with
obstruction or perforation, whether there was evidence
of venous or perineural invasion, and whether blood
transfusion had taken place, all of which are important
prognosticators. However, our results are hypothesis-
generating and can serve as a platform to further evalu-
ate and explain the survival paradox.
Conclusions
Based on our analysis of nearly 35,000 patients, we
confirmed that a survival paradox between Stage IIIA
and Stage IIB/C colon cancer patients exists for cases
diagnosed in 2003–2012 in the ACoS’ hospitals. Although
inadequate lymph nodes retrieved and lack of receipt of
adjuvant chemotherapy contributes to stage IIB/C poor
survival compared to stage IIIA, they themselves do not
entirely explain the paradox. Further studies are necessary
Table 3 Multivariable analysis (After Matching) of factors associated
with overall survival
Variable HR 95 % CI P-value
Stage
Stage IIB/C 1.52 (1.44,1.60) <.0001
Stage IIIA 1.00 – –
Age
18–49 – – –
50–64 1.24 (1.06, 1.44) 0.006
65–74 1.70 (1.44, 1.99) <.0001
75 and more 2.85 (2.43, 3.35) <.0001
Race/Ethnicity
White 1.00 – –
Black 1.18 (1.09, 1.28) <.0001
American Indian, Aleutian, or Eskimo 1.15 (0.71, 1.87) 0.57
Asian or Pacific Islander 0.76 (0.62, 0.94) 0.01
Other 0.73 (0.45, 1.18) 0.20
Facility Type
Community cancer program 1.29 (1.18, 1.40) <.0001
Comprehensive community cancer center 1.15 (1.08, 1.22) <.0001
Academic research program 1.00 – –
Facility Location
New England 1.00 (0.88, 1.14) 0.98
Mid Atlantic 0.99 (0.90, 1.10) 0.91
South Atlantic 0.95 (0.87, 1.05) 0.32
East North Central 0.95 (0.87, 1.05) 0.31
East South Central 0.98 (0.87, 1.11) 0.79
West North Central 1.02 (0.91, 1.15) 0.68
West South Central 0.96 (0.85, 1.08) 0.46
Mountain 0.91 (0.79, 1.06) 0.25
Pacific 1.00 – –
Urban/Rural Location
Metro ≥1 million 1.00 – –
Metro 250 k to 1 million 1.02 (0.96, 1.08) 0.56
Urban <250 k 0.95 (0.87, 1.03) 0.22
Urban≥ 20 k adjacent metro 0.98 (0.87, 1.11) 0.75
Urban≥ 20 k not adjacent metro 0.89 (0.73, 1.08) 0.24
Urban <20 k adjacent metro 0.98 (0.87, 1.10) 0.68
Urban <20 k not adjacent metro 1.10 (0.94, 1.28) 0.25
Rural <2500 adjacent metro 0.93 (0.72, 1.21) 0.57
Rural <2500 not adjacent metro 0.90 (0.71, 1.14) 0.38
Comorbidities
0 1.00 – –
1 1.26 (1.19, 1.33) <.0001
2 1.65 (1.53, 1.77) <.0001
Table 3 Multivariable analysis (After Matching) of factors associated
with overall survival (Continued)
Primary Site
Cecum 1.00 – –
Ascending Colon 1.00 (0.93, 1.08) 0.99
Hepatic Flexure 1.02 (0.90, 1.16) 0.72
Transverse Colon 0.97 (0.88, 1.06) 0.45
Splenic Flexure 1.16 (0.99, 1.35) 0.07
Descending Colon 1.06 (0.95, 1.19) 0.31
Sigmoid Colon 0.98 (0.92, 1.05) 0.58
Overlapping Lesions 0.92 (0.70, 1.20) 0.54
Not Otherwise Specified 1.39 (1.17, 1.66) 0.0002
Readmission within 30 days of Surgery
Not readmitted 1.00 – –
Readmitted 1.21 (1.12, 1.31) <.0001
Grade
Well differentiated 1.00 – –
Moderately differentiated 1.07 (0.98, 1.16) 0.12
Poorly differentiated 1.20 (1.09, 1.32) 0.0002
Undifferentiated, anaplastic 1.21 (1.00, 1.47) 0.05
Regional Lymph Nodes Examined
0–11 1.30 (1.23, 1.37) <.0001
12–90 1.00 – –
Chemotherapy
Yes 1.00 – –
No 2.24 (2.11, 2.37) <.0001
Surgical Margins
No residual tumor 1.00 – –
With Residual tumor 1.56 (1.29, 1.89) 0.003
Chu et al. BMC Cancer  (2016) 16:460 Page 8 of 9to determine other factors that also contribute to the
paradox, including our hypothesis that stage IIB/C is
inherently more aggressive than stage IIIA. Future
iteration of AJCC staging of colon cancer should consider
reconciling this paradox.
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